Elevai Biosciences has engaged KCRN Research to support the Company’s initial efforts to prepare for an Investigational New Drug application to the FDA for EL-22 in the treatment of obesity
Elevai Biosciences has engaged KCRN Research to support the Company’s initial efforts to prepare for an Investigational New Drug application to the FDA for EL-22 in the treatment of obesity
Elevai Biosciences, a subsidiary of Elevai Labs (ELAB), released past preclinical data from 2022 for EL-32, a pioneering dual-action blocker targeting myostatin and activin-A. Preclinical results generated from our licensing
Elevai Labs filed two novel patent applications for its lead candidate, EL-22, aimed at treating muscle loss in obese patients. These patent applications cover both standalone and combination therapies using
Elevai Labs announced the initiation of a clinical study to assess the efficacy of a topical exosome product in conjunction with an energy device treatment on facial skin appearance. The
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Elevai Labs (ELAB), 132% surge in interest Avidity Biosciences